On May 21, 2025, Neurocrine Biosciences held its Annual Meeting where shareholders approved the 2025 Equity Incentive Plan and the Amended and Restated Employee Stock Purchase Plan, among other measures, with significant support for each proposal reported. A total of 90,434,193 shares voted at the meeting.